{"entity":{"id":"amanitin-payloads","kind":"term","name":"Amanitin payloads","aka":["alpha-amanitin payload","amatoxin payloads","antibody-targeted amanitin conjugates","ATAC payloads","tismanitin"],"tldr":"Amanitin payloads block the machinery that copies genes into messages. Attaching them to an antibody aims to direct their cell-killing action toward cancer cells.","summary":"Amanitin derivatives inhibit RNA polymerase II. HDP-101, also called pamlectabart tismanitin, links an amanitin derivative to an antibody against BCMA. Published preclinical work found activity in proliferating and resting myeloma cells and tumor regression in mouse models. The linked human trial is a separate safety and activity study. The toxicity of free amanitin and preclinical tolerability of a conjugate must not be treated as the same safety evidence.","asOf":"2026-11-08","links":[{"label":"HDP-101 preclinical study (2021)","url":"https://doi.org/10.1158/1535-7163.MCT-20-0287"},{"label":"ClinicalTrials.gov: NCT04879043","url":"https://clinicaltrials.gov/study/NCT04879043"},{"label":"Papacharisi et al.: TROP2 amanitin-conjugate preclinical study (2025)","url":"https://pubmed.ncbi.nlm.nih.gov/39564769/"},{"label":"Letschert et al.: human-hepatocyte amatoxin transport (2006)","url":"https://pubmed.ncbi.nlm.nih.gov/16495352/"},{"label":"HDP-101 Chinese phase 1 study and source eligibility discrepancy","url":"https://clinicaltrials.gov/study/NCT07529782"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":["polr2a"],"drugs":["pamlectabart-tismanitin"],"companies":[],"institutions":[],"pathways":[],"terms":["payload","transcription-inhibitor-payloads"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["The active target is RNA polymerase II, whose largest subunit is encoded by POLR2A. BCMA or TROP2 can instead be the antibody delivery address. A source identifying one does not identify the other.","Papacharisi tested TROP2-directed amanitin conjugates in cells and pancreatic/TNBC xenografts. Potency, reported serum stability and tumor eradication belong to those constructs and models. Their comparison with Trodelvy is not a randomized human comparison.","The Letschert uptake experiments identified OATP1B3-mediated amatoxin transport in engineered cells and primary human hepatocytes. Passive permeability, bystander activity and normal-organ toxicity still need evaluation for the actual released species; they cannot be assigned from the toxin-family name.","HDP-101 is being evaluated in separately registered dose-finding/expansion studies. The registry does not establish response benefit, a safe dose or prospective validation of POLR2A or 17p selection. The Chinese study has a source age-field inconsistency, described on the drug record; a generated eligibility summary is not sufficient."],"category":"ADC chemistry"},"route":"/terms/amanitin-payloads/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"polr2a","kind":"target","name":"POLR2A","route":"/targets/polr2a/"}],"drug":[{"id":"pamlectabart-tismanitin","kind":"drug","name":"Pamlectabart tismanitin","route":"/drugs/pamlectabart-tismanitin/"}],"term":[{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"},{"id":"transcription-inhibitor-payloads","kind":"term","name":"Transcription-inhibitor payloads","route":"/terms/transcription-inhibitor-payloads/"}]}}